Company intelligence / Profile preview

Cotde

Philadelphia, Pennsylvania, USA6sense.com ↗

Ownership: Private
Development stage: Commercial

Overview

Code Biotherapeutics is developing a proprietary non-viral gene therapy platform called 3DNA®, designed to overcome key limitations of current genetic medicine approaches. The company’s most advanced research targets Duchenne muscular dystrophy and Type 1 diabetes. Internal pipeline programs are in preclinical stages with the goal of enabling future clinical trials. The company has raised significant venture funding to expand its pipeline and manufacturing capabilities.

Therapeutic areas: EndocrinologyRare Diseases
Modalities: Gene therapyDNA delivery platformSynthetic DNA-based therapyNon-viral gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Cotde.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cotde.

Explore the full profile